The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) increased its drug approval volume to 921 authorizations in the last year, a rise of 62 products over the previous period. According to the agency’s 2025-2026 annual report to Parliament, this performance included the approval of 39 new drugs, alongside record enforcement actions that removed 28.5 million doses of illegal medication from the UK supply chain.
Regulatory Efficiency and Patient Access
MHRA CEO Lawrence Tallon stated that the agency’s primary objective over the last year was to restore performance at the agency and create the conditions for it to grow. The agency met its internal assessment timelines for all clinical trial and national medicines license applications. A core component of this strategy involves the new MHRA-NICE pathway, a joint initiative with the National Institute for Health and Care Excellence designed to compress the time required for patient access to new treatments. In some cases, the agency reports that this collaborative model has reduced the wait time for patient access to as little as six months.
Did you know?
The MHRA’s Clinical Practice Research Datalink (CPRD) is now actively utilized to generate real-world evidence, supporting the agency’s goal of using data-driven insights to speed up the regulatory process for new medicines.
Combating the Illegal Medicines Trade
Enforcement operations led by the MHRA resulted in the seizure of 28.5 million doses of illicit drugs, valued at an estimated $86.5 million. A significant milestone in these efforts occurred in October 2025, when the agency dismantled the UK’s first known counterfeit weight loss drug manufacturing facility in Northampton. According to the MHRA, the raid uncovered thousands of unlicensed injection pens containing substances such as tirzepatide and retatrutide. Follow-up investigations in February 2026, conducted alongside the police, Immigration Enforcement, and Trading Standards, targeted the criminal network’s distribution infrastructure, seizing additional manufacturing equipment and vehicles.
Frameworks for AI and Emerging Technologies
The MHRA is positioning itself to manage the integration of artificial intelligence in clinical settings. The agency established the National Commission into the Regulation of AI in Healthcare to advise on future regulatory frameworks. Practical testing of these technologies is being conducted through the “AI Airlock,” a regulatory sandbox that allows developers to test emerging tools in a controlled environment. These efforts are part of a broader push to harmonize UK regulations with global standards, including the agency’s leadership role in the ACCESS consortium.
Pro Tip:
For innovators looking to bring new medical devices to the UK market, the agency’s focus on “proportionate and agile” regulation suggests that early engagement with the AI Airlock project may be a critical step in navigating the approval process.
Future Strategy and Institutional Growth
Following the publication of the 2025-2026 report, the agency is preparing to release its “MHRA2030 Strategy.” This document is expected to detail the agency’s long-term plan for sustaining performance and modernizing regulatory oversight. With $10 million in new research grants secured for regulatory science, the agency aims to maintain its current momentum while addressing the complexities of rare disease therapies and medical device reform.
Frequently Asked Questions
How many new drugs did the MHRA approve in the last year?
The MHRA approved 921 drugs for the UK market, which included 39 new drug approvals. This represents an increase of 62 approvals compared to the previous year.
What is the MHRA-NICE pathway?
It is a joint regulatory initiative between the MHRA and the National Institute for Health and Care Excellence. The pathway is designed to align regulatory and health technology assessments to accelerate patient access to new treatments, with some processes completed in as little as six months.
What is the purpose of the AI Airlock?
The AI Airlock serves as a regulatory sandbox. It allows the MHRA to test emerging artificial intelligence technologies in a controlled environment before they are widely deployed in the UK healthcare system.
Where can I find more information on the agency’s future plans?
The agency’s upcoming “MHRA2030 Strategy” will outline its plans for modernizing the agency, sustaining performance, and supporting life sciences innovation. You can track progress on the official MHRA website.
Are you involved in the UK life sciences sector? Share your thoughts on the new regulatory pathways in the comments below, or subscribe to our newsletter for the latest updates on medical regulation and healthcare innovation.